ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
Piper Sandler downgraded Supernus Pharmaceuticals Inc (NASDAQ:SUPN), saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected.
派珀·桑德勒下調了Supernus Pharmicals Inc（納斯達克股票代碼：SUPN）的評級，稱返校季Qelbree處方的預期激增並未如預期的那樣實現。
"That has us rethinking our assumptions regarding the longer-term (LT) sales/volume growth trajectory of the product," the analyst adds.
分析師補充說：「這讓我們重新考慮了對該產品的長期（LT）銷售/銷量增長軌跡的假設。」
Qelbree (viloxazine) is indicated to treat attention deficit hyperactivity disorder in children and adults.
Qelbree（維洛沙嗪）適用於治療兒童和成人的注意力缺陷多動障礙。
In the second quarter of 2024, net sales of Qelbree increased 92% year over year to $59.4 million, and total IQVIA prescriptions were 184,342, up 26%.
在2024年第二季度，Qelbree的淨銷售額同比增長92％，達到5,940萬美元，IQVIA處方總額爲184,342張，增長26％。
Piper writes that the management's focus on optimizing Qelbree's net economics, such as reducing copay assistance, suggests that future volume growth may be more modest. While initial estimates projected peak sales nearing $500 million, Piper writes that $400 million is a more realistic target.
派珀寫道，管理層專注於優化Qelbree的淨經濟效益，例如減少自付額補助，這表明未來的銷量增長可能更爲溫和。儘管最初的估計預計峯值銷售額接近5億美元，但派珀寫道，4億美元是一個更現實的目標。
The Piper analyst writes that Qelbree is growing and highlights that YTD prescriptions increased 91% in 2023 compared to 2022.
派珀分析師寫道，Qelbree正在增長，並強調與2022年相比，2023年年初至今的處方量增長了91％。
Piper has downgraded Supernus Pharmaceuticals to Neutral from Overweight, with a price target of $36, down from $41.
派珀已將Supernus Pharmicals的評級從增持下調至中性，目標股價從41美元下調至36美元。
Quarter-to-date prescriptions have grown by about 1% in the third quarter of 2024 compared to the second quarter, following a 4% increase in the second quarter over the first quarter. In contrast, prescriptions for all ADHD products have declined sequentially by around 2% quarter-to-date in the third quarter.
繼第二季度較第一季度增長4％之後，2024年第三季度迄今爲止的處方藥量與第二季度相比增長了約1％。相比之下，所有注意力缺陷多動障礙產品的處方在第三季度迄今已連續下降了約2％。
A Piper analyst expects volume growth for Qelbree to accelerate during the back-to-school season but anticipates a slower growth trajectory than initially expected, prompting a reassessment of the drug's peak sales potential.
派珀的一位分析師預計，在返校季，Qelbree的銷量增長將加速，但預計增長軌跡將低於最初的預期，這促使人們重新評估該藥的峯值銷售潛力。
In August, the FDA acknowledged the resubmission of the new drug application (NDA) for the company's apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease.
8月，美國食品藥品管理局承認重新提交了該公司用於持續治療帕金森氏病運動波動（OFF發作）的阿撲嗎啡輸液設備（SPN-830）的新藥申請（NDA）。
The resubmission is now filed, with a user fee goal date (PDUFA date) of February 1, 2025.
重新提交的申請現已提交，用戶費用目標日期（PDUFA日期）爲2025年2月1日。
In April, the FDA issued a Complete Response Letter related to SPN-830, requiring additional information regarding the product quality and the master file for the infusion device.
4月，美國食品和藥物管理局發佈了與 SPN-830 相關的完整回覆信，要求提供有關輸液設備產品質量和主文件的更多信息。
Price Action: SUPN stock is down 7.17% at $31.09 at last check Wednesday.
價格走勢：週三最後一次檢查時，SUPN股價下跌7.17％，至31.09美元。
Photo via Shutterstock
照片來自 Shutterstock
- Chinese EV Manufacturers BYD And Geely Storm Frankfurt Fair As EU Tariffs Threaten To Crimp Their Global EV Push: Report.
- 中國電動汽車製造商比亞迪和吉利衝擊法蘭克福博覽會，因爲歐盟的關稅有可能抑制其全球電動汽車的發展：報告。
譯文內容由第三人軟體翻譯。